An implementation of PD-L1 as a reliable biomarker for selecting or excluding patients with BC for immunotherapy was complicated by several challenges, mainly related to molecular and cellular heterogeneity of the disease and the methodology used to measure PD-L1 expression. This evidence concerns the gene CD274 and breast cancer.